MarketMoodz
Morgan Stanley Upgrades ARWR to Overweight; PT $100 Ahead of Phase 3
Morgan Stanley upgrades Arrowhead Pharmaceuticals (ARWR) to overweight and lifts its price target to $100 as Phase 3 data for Plozasiran (Redemplo) in severe hypertriglyceridemia looms in 3Q26. The move adds momentum to a stock that has surged roughly 473% over the past year.
Key Takeaways
- Morgan Stanley lifts ARWR to overweight with a $100 price target, about 44% upside to the prior close
- Phase 3 data for Plozasiran (Redemplo) in severe hypertriglyceridemia is expected in 3Q26, driving investor momentum
- LSEG consensus shows 10 of 13 analysts rate ARWR as buy or strong buy
- ARWR has advanced roughly 473% over the past year
- SHTG pipeline could offer a multibillion-dollar opportunity if Phase 3 results are positive, though timing and outcomes remain uncertain
People Involved
- Michael Ulz Morgan Stanley Analyst
Entities Involved
- Arrowhead Pharmaceuticals (ARWR) Biotech company developing RNA interference therapies including Plozasiran (Redemplo) for severe hypertriglyceridemia
- Morgan Stanley Financial services firm providing equity research and investment banking coverage
MarketMoodz Analysis
The upgrade reframes Arrowhead’s risk-reward as key Phase 3 data for Plozasiran readouts in 3Q26 approach. A positive readout could accelerate a revaluation of the stock, while a setback would test the stock’s momentum and the wider RNAi space. Investors should weigh trial execution risk, potential regulatory hurdles, and competition from other RNAi programs.
Historically, biotech upgrades ahead of catalysts have powered meaningful, though sometimes temporary, repricings. Arrowhead’s shares have sprinted higher on phase-gate optimism and sector bullishness, but the fundamental economics hinge on durable efficacy and safety signals that translate into formal regulatory approval and market uptake. The note’s emphasis on a multibillion-dollar SHTG opportunity underscores pipeline optionality, though that potential is contingent on Phase 3 success and market dynamics.
Next catalysts to monitor include the 3Q26 Plozasiran data readout, any regulatory updates, and how the stock reacts to interim trial signals or sponsor communications. A sustained push higher would likely depend on a clear, durable Phase 3 win and continued execution within Arrowhead’s broader RNAi portfolio.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial